GSK CEO Emma Walmsley with Endpoints' Drew Armstrong at the Financial Times' Global Pharma and Biotech Summit (courtesy Financial Times)
November 6, 2024 01:49 PM EST
People
China
AI
Pharma

GSK CEO Em­ma Walm­s­ley on the new Trump ad­min­is­tra­tion, trust, AI and Chi­na

Drew Armstrong

Executive Editor

De­spite the rise of a vac­cine skep­tic in the cam­paign of US pres­i­den­tial elec­tion win­ner Don­ald Trump, GSK CEO Em­ma Walm­s­ley be­lieves her com­pa­ny can …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

Mer­ck’s long-await­ed obe­si­ty move is an oral GLP-1 from Chi­na

Ma­jor PBM re­forms fea­ture in Con­gress' year-end spend­ing bill

What Trump’s FTC picks mean for bio­phar­ma deal­mak­ing and PBMs

Up­dat­ed: Ver­tex’s non-opi­oid pill dis­ap­points in mid-stage chron­ic pain study

A service from the Financial Times